Durvalumab vs Lutetium Lu-177 Vipivotide Tetraxetan

## Durvalumab vs Lutetium Lu-177 Vipivotide Tetraxetan: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Lutetium Lu-177 Vipivotide Tetraxetan**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Lutetium Lu-177 Vipivotide Tetraxetan — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Lutetium Lu-177 Vipivotide Tetraxetan — Protein.